Published: Sun, October 18, 2020
Medical | By

Colorado officials outline how a COVID-19 vaccine would be distributed

Colorado officials outline how a COVID-19 vaccine would be distributed

However, this action will occur only if the safety and efficacy of the drug can be guaranteed created together with the BioNTech company.

Dr. Soumya Swaminathan, WHO chief scientist, said COVID-19 vaccines will hopefully come in 2021, however, quantities will be limited.

"I think most people agree that the people at highest risk of both transmission, getting the disease, and getting sick from it are healthcare workers, frontline workers, and then the elderly and the vulnerable, " she said, adding that a healthy, young person might have to wait until 2022 to get vaccinated because of the massive amounts of vaccine that will be needed to protect the first groups.

"So let me be clear, assuming positive data, Pfizer will apply for Emergency Authorization Use in the USA soon after the safety milestone is achieved in the third week of November", Mr. Bourla wrote in an open letter. "All the data contained in our USA application would be reviewed not only by the FDA's own scientists but also by an external panel of independent experts at a publicly held meeting convened by the agency".

Pfizer's predictions mean that its vaccine, called BNT162b2, may not be ready before the U.S. elections, as the president of the country, Donald Trump, had said on occasion, who stated that he expected this drug, of which he has already reserved 100 million doses, would be the first to be approved in the United States. Its CEO repeatedly pointed to late October as a critical point for knowing more about its progress. "This protein is what the virus uses to penetrate the cells of our body and replicate ".

If there's a sufficient supply, ME says it would have the capacity to vaccinate 80 percent of the state's 1.3 million people within 12 weeks of when a vaccine becomes available.

But the rush to develop a vaccine has raised concerns that the U.S. Food and Drug Administration, acting in haste, might not conduct an adequate review.

Shah said that's just one of the distribution challenges, but nevertheless, they are working out scenarios based on the vaccines now in late-stage trials.

One bright sign is that Covid-19 treatments have improved markedly, and since the cases are more spread out than before, hospitals aren't being overwhelmed.

Two vaccinations by the end of the year?

United States (US) biotech firm Moderna, a US-German collaboration between BioNTech and Pfizer, several state-run Chinese labs, and a European project led by the University of Oxford and AstraZeneca are thought to be among the more promising.

Both Pfizer and Moderna began phase three of their clinical trials in late July and both have started dose production, to be in a position to distribute tens of millions in the United States by the end of the year.

The company said it hopes to move ahead with the vaccine after safety data is available in the third week of November, immediately lifting the company's shares two percent in the US.

Bourla said Pfizer is "operating at the speed of science", but there are three steps that must happen before the company can release its COVID-19 vaccine. Three were in Moderna's trial, while the other two were in Pfizer's.

Like this: